Free Trial
NASDAQ:SCPS

Scopus BioPharma (SCPS) Stock Price, News & Analysis

Scopus BioPharma logo
$0.0003 0.00 (0.00%)
As of 05/19/2025 09:33 AM Eastern

About Scopus BioPharma Stock (NASDAQ:SCPS)

Key Stats

Today's Range
$0.0003
$0.0003
50-Day Range
N/A
52-Week Range
$0.0001
$0.01
Volume
586 shs
Average Volume
2,056 shs
Market Capitalization
$12,625.20
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Receive SCPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scopus BioPharma and its competitors with MarketBeat's FREE daily newsletter.

SCPS Stock News Headlines

Scopus Biopharma Inc Price / Book
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
Scopus Biopharma Inc (SCPS)
ArriVent BioPharma Inc AVBP
Scopus BioPharma Inc. (SCPS)
See More Headlines

SCPS Stock Analysis - Frequently Asked Questions

Scopus BioPharma's stock was trading at $0.0003 at the beginning of the year. Since then, SCPS stock has increased by 0.0% and is now trading at $0.0003.
View the best growth stocks for 2025 here
.

Shares of SCPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Scopus BioPharma investors own include Plug Power (PLUG), Canoo (GOEV), NIO (NIO), SNDL (SNDL), Tesla (TSLA), Moderna (MRNA) and VYNE Therapeutics (VYNE).

Company Calendar

Today
5/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SCPS
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
39,938,000
Market Cap
$12,625.20
Optionable
Not Optionable
Beta
-0.29
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:SCPS) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners